IN THE SPECIFICATION:

Please amend the specification as follows:

Please replace paragraph [0001] with the following paragraph:

[0001] This application is a Divisional of U.S. Serial No. 09/706,540 filed November 4, 2000, now U.S. Patent No. 6,689,753, issued February 10, 2004, which claims priority from U.S. Provisional Application No. 60/163,911, which was filed on November 5, 1999.

Please replace the paragraph under the Abstract heading with the following paragraph:

ABSTRACT

The present invention is an inhibitory peptide capable of inhibiting β pleated sheet formation in amyloid β peptide. The inhibitory peptide is a β -sheet breaker peptide analog designed by chemical modification of a β -sheet breaker peptide capable of inhibiting β pleated sheet formation in amyloid β -peptide.

The present invention also includes an inhibitory peptide capable of inhibiting conformational changes in prion PrP protein associated with amyloidosis. The inhibitory peptide being a β sheet breaker peptide analog designed by chemical modification of a β sheet breaker peptide capable inhibiting said conformational changes in prion PrP protein associated with amyloidosis.

In addition, the present invention includes a peptide mimetic with the following structure:

PMiAB5

In another embodiment, the peptide mimetic has the following structure:

PMiPrP13

In yet another embodiment, the peptide mimetic has the following structure:

$$H_3$$
C CH_3 $COOH$ $COOH$ $COOH$ CH_3 CH_3 CH_3 CH_3 $COOH$ $COOH$

PMiPrP5

The present invention provides peptide analogs and peptide mimetics that inhibit pleated sheet formation in amyloid β -peptide, pharmaceutical compositions thereof and their therapeutic use. The inhibitory peptides possess activity as inhibitors in the formation of amyloid-like deposits and are useful in the treatment of Alzheimer's Disease.